ACHN Achillion Pharmaceuticals Inc.

6.09
-0.11  -2%
Previous Close 6.2
Open 6.15
Price To Book 3.67
Market Cap 850,729,810
Shares 139,692,908
Volume 6,388,061
Short Ratio
Av. Daily Volume 2,765,027
Stock charts supplied by TradingView

NewsSee all news

  1. Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  2. Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

    – Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.

  3. Achillion to Present at the Baird 2019 Global Healthcare Conference

    BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 full data due 4Q 2019.
Danicopan (ACH-4471)
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Phase 2 trial planned with Phase 3 trials to potentially commence in early 2020.
ACH-5228
Healthy volunteers

Latest News

  1. Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by

  2. Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

    – Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.

  3. Achillion to Present at the Baird 2019 Global Healthcare Conference

    BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by